Drugs / DCRCC-RNA
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00006431 | — | renal cell carcinoma | National Center for Research Resources (NCRR) | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DCRCC-RNA | “The feasibility and dose-limiting toxicity of administering escalating doses of dendritic cells transfected with autologous renal cell carcinoma RNA DC(DCRCC-RNA) will be defined.” NCT00006431 ↗ |
| Route | Intravenous | “one I.V.” NCT00006431 ↗ |